undamentalytics Newsletter
Sign in

Aligos Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Aligos Therapeutics, Inc. had total assets of $88.5m, total liabilities of $35.0m and shareholders' equity of $53.5m. It held $18.3m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents22018781136371830
Receivables——————28
Total current assets250204134141628362
Total assets265235147152708966
Accounts payable3353346
Deferred revenue (current)8——100—
Total current liabilities30393324222128
Total debt0000000
Total liabilities45514359993534
Shareholders' equity22018510492−295432
Shares outstanding———3m———

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ALGS vs DYAIALGS vs DBVTALGS vs CAMPALGS vs XBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aligos Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aligos Therapeutics, Inc.